STOCK TITAN

Vicarious Surgical Announces Departure of Chief Financial Officer

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Vicarious Surgical (NYSE: RBOT) announced that Chief Financial Officer William Kelly will be departing the company on January 2, 2025. Kelly, who has served as CFO since January 2021, is leaving to pursue other career opportunities after nearly four years with the company.

Kelly will assist in ensuring a smooth transition of responsibilities before his departure. The company has initiated a CFO succession process and will provide updates accordingly. CEO Adam Sachs expressed gratitude for Kelly's significant contributions during his tenure.

Vicarious Surgical (NYSE: RBOT) ha annunciato che il Chief Financial Officer William Kelly lascerà l'azienda il 2 gennaio 2025. Kelly, che ricopre il ruolo di CFO dal gennaio 2021, sta lasciando per perseguire altre opportunità professionali dopo quasi quattro anni in azienda.

Kelly assisterà per garantire una transizione fluida delle responsabilità prima della sua partenza. L'azienda ha avviato un processo di successione per il CFO e fornirà aggiornamenti a riguardo. Il CEO Adam Sachs ha espresso gratitudine per i significativi contributi di Kelly durante il suo mandato.

Vicarious Surgical (NYSE: RBOT) anunció que el Director Financiero William Kelly dejará la empresa el 2 de enero de 2025. Kelly, que ha sido CFO desde enero de 2021, se marcha para seguir otras oportunidades profesionales tras casi cuatro años en la empresa.

Kelly ayudará a asegurar una transición suave de responsabilidades antes de su partida. La empresa ha iniciado un proceso de sucesión para el CFO y proporcionará actualizaciones al respecto. El CEO Adam Sachs expresó su agradecimiento por las importantes contribuciones de Kelly durante su mandato.

Vicarious Surgical (NYSE: RBOT)는 최고 재무 책임자(CFO) 윌리엄 켈리가 2025년 1월 2일에 회사를 떠날 것이라고 발표했습니다. 켈리는 2021년 1월부터 CFO로 재직했으며, 거의 4년 동안 회사를 다닌 후 다른 경력 기회를 추구하기 위해 떠나는 것입니다.

켈리는 떠나기 전에 책임 이양이 원활하게 이루어질 수 있도록 도울 것입니다. 회사는 CFO 후임 절차를 시작했으며, 이에 대한 업데이트를 제공할 것입니다. CEO 아담 삭스는 켈리가 재임 기간 동안 기여한 바에 대해 감사를 표했습니다.

Vicarious Surgical (NYSE: RBOT) a annoncé que son directeur financier William Kelly quittera l'entreprise le 2 janvier 2025. Kelly, qui occupe le poste de CFO depuis janvier 2021, part pour poursuivre d'autres opportunités professionnelles après près de quatre ans passés dans l'entreprise.

Kelly aidera à garantir une transition en douceur des responsabilités avant son départ. L'entreprise a lancé un processus de succession pour le poste de CFO et fournira des mises à jour en conséquence. Le PDG Adam Sachs a exprimé sa gratitude pour les importantes contributions de Kelly durant son mandat.

Vicarious Surgical (NYSE: RBOT) gab bekannt, dass der Finanzvorstand William Kelly das Unternehmen zum 2. Januar 2025 verlassen wird. Kelly, der seit Januar 2021 CFO ist, verlässt das Unternehmen, um andere Karrieremöglichkeiten zu verfolgen, nachdem er fast vier Jahre lang dort tätig war.

Kelly wird beim reibungslosen Übergang der Verantwortlichkeiten vor seiner Abreise helfen. Das Unternehmen hat einen Nachfolgeprozess für den CFO eingeleitet und wird entsprechende Updates zur Verfügung stellen. CEO Adam Sachs drückte seine Dankbarkeit für Kellys bedeutende Beiträge während seiner Amtszeit aus.

Positive
  • None.
Negative
  • Departure of key executive (CFO) after nearly 4 years of service

WALTHAM, Mass.--(BUSINESS WIRE)-- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the pending departure of William Kelly, its Chief Financial Officer (CFO), to pursue other career opportunities, after nearly four years of dedicated service with the Company.

Mr. Kelly has served as Vicarious Surgical’s CFO since January 2021. He will assist the Company to ensure minimal disruption and a successful transition of responsibilities prior to his departure, which is slated for January 2, 2025.

“On behalf of the Company and Board, I want to extend my sincerest gratitude to Bill for his significant contribution over the last few years,” said Adam Sachs, Co-Founder and Chief Executive Officer. “Bill has been an incredible asset to Vicarious Surgical, and we wish him all the best in his future endeavors.”

Mr. Kelly added “My tenure at Vicarious Surgical has been a period of significant progress and accomplishment, both for the Company and for me personally. I am deeply grateful for the opportunities I have been afforded and the collaborative spirit of the entire team. I depart with immense pride in our collective achievements and unwavering confidence in the Company's continued success under its strong leadership.”

The Company has initiated a CFO succession process and will provide updates as appropriate.

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in-license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Investors

Kaitlyn Brosco

Vicarious Surgical

Kbrosco@vicarioussurgical.com



Media Inquiries

media@vicarioussurgical.com

Source: Vicarious Surgical Inc.

FAQ

When is Vicarious Surgical (RBOT) CFO William Kelly leaving the company?

William Kelly will be departing Vicarious Surgical on January 2, 2025.

How long has William Kelly served as CFO of Vicarious Surgical (RBOT)?

William Kelly has served as Vicarious Surgical's CFO since January 2021, nearly four years.

What is the reason for Vicarious Surgical (RBOT) CFO's departure?

William Kelly is leaving Vicarious Surgical to pursue other career opportunities.

Has Vicarious Surgical (RBOT) named a replacement for departing CFO William Kelly?

No, the company has initiated a CFO succession process and will provide updates as appropriate.

Vicarious Surgical Inc.

NYSE:RBOT

RBOT Rankings

RBOT Latest News

RBOT Stock Data

69.88M
3.86M
26.56%
35.93%
1.12%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
WALTHAM